A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
Phase of Trial: Phase III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Trebananib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRINOVA-1
- Sponsors Amgen; Takeda
- 10 Jun 2017 Biomarkers information updated
- 19 Dec 2016 This trial has been Discontinued in Czech Republic according to European Clinical Trials Database record.
- 14 Dec 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History